ZEJULA (niraparib) logo

Product menu

Fictious Healthcare professional

Recommended dosing

ZEJULA (niraparib) is a first-line maintenance treatment that offers your patients convenient once-daily oral dosing1

Could your patients benefit from the only once-daily PARP inhibitor with an individualised starting dose?1

Once daily icon

Once-daily oral monotherapy

Time icon

Taken any time of the day*

Outline of patient

Without the constraints of infusion

Image of two white tablets

Individualised starting dose

Downward trending arrow

Limited DDIs and manageable safety and tolerability profile

WHAT ABOUT ZEJULA EFFICACY?

Find out more

PRIME efficacy

PRIMA efficacy

PRIME study design

PRIMA study design

ZEJULA is indicated

  • as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
  • as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Footnotes

*ZEJULA should be taken at approximately the same time each day.1

Abbreviations

ADP, adenosine diphosphate; AEs, adverse events; DDIs, drug-drug interactions; FIGO, Federation of Gynaecology and Obstetrics; PARP, poly(ADP-ribose)polymerase.

Reference

  1. ZEJULA (niraparib). Summary of product characteristics.

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk (UK) or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to GSK Limited on 0800 221 441 or by email at uksafety@gsk.com.

©2023 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

June 2023 | PM-GB-NRP-WCNT-220024 (V1.0)